1. bookVolume 14 (2011): Issue 2 (December 2011)
Journal Details
License
Format
Journal
eISSN
2199-5761
ISSN
1311-0160
First Published
10 Oct 2007
Publication timeframe
2 times per year
Languages
English
access type Open Access

Amplification of c-MYC and MLL Genes as a Marker of Clonal Cell Progression in Patients with Myeloid Malignancy and Trisomy of Chromosomes 8 or 11

Journal Details
License
Format
Journal
eISSN
2199-5761
ISSN
1311-0160
First Published
10 Oct 2007
Publication timeframe
2 times per year
Languages
English
Amplification of <italic>c-MYC</italic> and <italic>MLL</italic> Genes as a Marker of Clonal Cell Progression in Patients with Myeloid Malignancy and Trisomy of Chromosomes 8 or 11

Gene amplification (amp) is one of the basic mechanisms connected with overexpression of oncogenes. The c-MYC (located in 8q24) and MLL (located in 11q23) are the most often over represented genes that lead to a rapid proliferation of the affected cell clone in patients with myeloid neoplasms. Assessment of the level of amp c-MYC or amp MLL in the cases with trisomy 8 (+8) or trisomy 11 (+11) and myeloid malignances is necessary for a more precise estimation of the disease progression.

A total of 26 patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) were included in the study: 18 with +8, six with +11 and two with complex karyotypes suspected of the partial trisomy. Routine cytogenetic analysis and fluorescent in situ hybridization (FISH) were applied to indicate the chromosome alterations and genes amp in the bone marrow cells.

Amp c-MYC was observed in 12 from 18 (66.7%) patients with +8. All the patients with +11 demonstrated a different level of amp MLL. In most of the cases with MDS (9/10), the coincidence of the +8 or +11 with amp c-MYC or amp MLL, respectively, leads to transformation to AML and/or short overall survival. Our data suggest that amp c-MYC and amp MLL develop in conformity with +8 and +11, especially in cases with progressive deviations in the karyotype as an aggressive expansion of an aberrant cell clone and appearance of additional chromosome anomalies.

Keywords

Albertson D G. Gene amplification in cancer. Trends Genet. 2006; 22(8): 447-455.10.1016/j.tig.2006.06.00716787682Search in Google Scholar

Gajduskova P, Snijders AM, Kwek S, Roydasgupta R, Fridlyand J, Tokuyasu T, Pinkel D, Albertson DG. Genome position and gene amplification. Genome Biol. 2007; 8(6): R120.1-16.10.1186/gb-2007-8-6-r120239477117584934Search in Google Scholar

Osthus RC, Karim B, Prescott JE, Smith BD, McDevitt M, Huso DL, Dang CV. The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo. Cancer Res. 2005; 65(13): 5620-5627.10.1158/0008-5472.CAN-05-0536122473415994934Search in Google Scholar

Poppe B, Vandesompele J, Schoch C, Lindvall C, Mrózek K, Bloomfield CD, Beverloo HB, Michaux L, Dastugue N, Herens C, Yigit N, De Paepe A, Hagemeijer A, Speleman F. Expression analyses identify MLL as a prominent target of 11q23 amplification and support an etiologic role for MLL gain of function in myeloid malignancies. Blood. 2004; 103(1): 229-235.10.1182/blood-2003-06-216312946992Search in Google Scholar

Andersen MK, Christiansen DH, Pedersen-Bjergaard J. Amplification or duplication of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML. Leukemia. 2005; 19(2): 197-200.10.1038/sj.leu.240361215618958Search in Google Scholar

Mauvieux L, Helias C, Perrusson N, Lioure B, Sorel N, Brizard F, Lessard M. ETV6 (TEL) gene amplification in a myelodysplastic syndrome with excess of blasts. Leukemia. 2004; 18(8): 1436-1438.10.1038/sj.leu.240340315175627Search in Google Scholar

Rayeroux KC, Campbell LJ. Gene amplification in myeloid leukemias elucidated by fluorescence in situ hybridization. Cancer Genet Cytogenet. 2009; 193(1): 44-5310.1016/j.cancergencyto.2009.04.00619602463Search in Google Scholar

Popovic R, Riesbeck LE, Velu CS, Chaubey A, Zhang J, Achille NJ, Erfurth FE, Eaton K, Lu J, Grimes HL, Chen J, Rowley JD, Zeleznik-Le NJ. Regulation of mir-196b by MLL and its overexpression by MLL fusions contributes to immortalization. Blood. 2009; 113(14): 3314-3322.10.1182/blood-2008-04-154310266589619188669Search in Google Scholar

Popescu NC, Zimonjic DB. Chromosome-mediated alterations of the MYC gene in human cancer. J Cell Mol Med. 2002; 6(2): 151-159.10.1111/j.1582-4934.2002.tb00183.x674013512169201Search in Google Scholar

Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008; 8(12): 976-990.10.1038/nrc223119029958Search in Google Scholar

Farag SS, Archerd KJ, Mrozek K, Vardiman JW, Carroll AJ, Pettenati MJ, Morre JO, Kolitz JE, Mayer RJ, Stone RM, Larson RA, Bloomfield CD. Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B 8461. Int J Oncol. 2002, 21(5): 1041-1051.10.3892/ijo.21.5.1041Search in Google Scholar

Grimwade D, Hills RK. Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program. 2009; 385: 385-395.10.1182/asheducation-2009.1.385Search in Google Scholar

Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PRK, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002; 100(13): 4325-4336.10.1182/blood-2002-03-0772Search in Google Scholar

Wolman SR, Gundacker H, Appelbaum FR, Slovak ML. Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. Blood. 2002; 100(1): 29-35.10.1182/blood.V100.1.29Search in Google Scholar

Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004, 18(2): 115-136.10.1016/S0268-960X(03)00040-7Search in Google Scholar

Malcovati L, Germing U, Kuendgen A, Della Porta MG, Pascutto C, Invernizzi R, Giagounidis A, Hildebrandt B, Bernasconi P, Knipp S, Strupp C, Lazzarino M, Aul C, Cazzola M. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol. 2007; 25(23): 3505-3510.10.1200/JCO.2006.08.569617687155Search in Google Scholar

Rucker FG, Bullinger L, Schwaenen C, Lipka DB, Wessendorf S, Fröhling S, Bentz M, Miller S, Scholl C, Schlenk RF, Radlwimmer B, Kestler HA, Pollack JR, Lichter P, Döhner K, Döhner H. Disclosure of candidate genes in acute myeloid leukemia with complex karyotypes using microarray-based molecular characterization. J Clin Oncol. 2006; 24(24): 3887-3894.10.1200/JCO.2005.04.545016864856Search in Google Scholar

Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T. Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia. 2002; 16(1): 53-59.10.1038/sj.leu.240232911840263Search in Google Scholar

International System for Human Cytogenetic Nomenclature (2009). Shaffer LG, Slovak ML, Campbell LJ, Eds. Basel: S. Karger, 2009.Search in Google Scholar

Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA, Bloomfield CD, de La Chapelle A, Krahe R. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci USA. 2001; 98(3): 1124-1129.10.1073/pnas.98.3.11241471911158605Search in Google Scholar

Schoch C, Kohlmann A, Dugas M, Kern W, Hiddemann W, Schnittger S, Haferlach T. Genomic gains and losses influence expression levels of genes located within the affected regions: a study on acute myeloid leukemias with trisomy 8, 11, or 13, monosomy 7, or deletion 5q. Leukemia. 2005; 19(7): 1224-1228.10.1038/sj.leu.240381015902281Search in Google Scholar

Chen G, Zeng W, Miyazato A, Billings E, Maciejewski JP, Kajigaya S, Sloand EM, Young NS. Distinctive gene expression profiles of CD34 cells from patients with myelodysplastic syndrome characterized by specific chromosomal abnormalities Blood. 2004; 104(13): 4210-4218.10.1182/blood-2004-01-0103Search in Google Scholar

Luo H, Li Q, O'Neal J, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood. 2005; 106(7): 2452-2461.10.1182/blood-2005-02-0734Search in Google Scholar

Jain AN, Chin K, Borresen-Dale A-L, Erikstein BK, Lonning PE, Kaaresen R, Gray JW. Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc Natl Acad Sci USA. 2001; 98(14): 7952-7957.10.1073/pnas.151241198Search in Google Scholar

Strout MP, Lorsbach RB, Shearer P, Sandlund JT, Raimondi SC. Double minute chromosomes and c-MYC amplification in a child with secondary myelodysplastic syndrome after treatment for acute lymphoblastic leukemia. Leukemia. 2000; 14(7): 1314-1315.10.1038/sj.leu.2401782Search in Google Scholar

Jennings BA, Mills KI. C-MYC locus amplification and the acquisition of trisomy 8 in the evolution of chronic myeloid leukaemia. Leuk Res. 1998; 22(10): 899-903.10.1016/S0145-2126(98)00097-6Search in Google Scholar

Slovak ML, Ho JP, Pettenati MJ, Khan A, Douer D, Lal S, Traweek ST. Localization of amplified MYC gene sequences of double minute chromosomes in acute myelogenous leukemia. Genes Chromosomes Cancer. 1994; 9(1): 62-67.10.1002/gcc.2870090111Search in Google Scholar

Storlazzi CT, Fioretos T, Paulsson K, Strömbeck B, Lassen C, Ahlgren T, Juliusson G, Mitelman F, Johansson RM. Identification of a commonly amplified 4.4 Mb region with overexpression of C8FW, but not MYC and MYC-containing double minutes in myeloid malignancies. Hum Mol Genet. 2004; 13(14): 1479-1485.10.1093/hmg/ddh164Search in Google Scholar

Whitman SP, Liu S, Vukosavljevic T, Rush LJ, Yu L, Liu C, Klisovic MI, Maharry K, Guimond M, Strout MP, Becknell B, Dorrance A, Klisovic RB, Plass C, Bloomfield CD. The MLL partial tandem duplication: evidence for recessice gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for moleculartargeted therapy. Blood. 2005; 106(1); 345-352.10.1182/blood-2005-01-0204Search in Google Scholar

Tyybäkinoja A, Saarinen-Pihkala U, Elonen E, Knuutila S. Amplified, lost and fused genes in 11q23-25 amplicon in acute myeloid leukemia, an array-CGH study. Genes Chromosomes Cancer. 2006; 45(3): 258-264.10.1002/gcc.20288Search in Google Scholar

Michaux L, Wlodarska I, Stul M, Dierlamm J, Mugneret F, Herens C, Beverloo B, Verhest A, Verellen-Dumoulin C, Verhoef G, Selleslag D, Madoe V, Lecomte M, DeprijckB, Ferrant A, Delannoy A, Marichal S, Duhem C, Dicato M, Hagemeiher A. MLL Amplification in myeoloid leukemias: a study of 14 cases with multiple copies of 11q23. Genes Chromosomes Cancer. 2000; 29(1): 40-47.10.1002/1098-2264(2000)9999:9999<::AID-GCC1003>3.0.CO;2-USearch in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo